AI Insights on Bowel Cancer Patients’ Reactions to New NHS Treatment

A groundbreaking artificial intelligence (AI) method has been introduced for predicting the response of patients with advanced bowel cancer to a newly approved drug by the NHS. This innovative approach aims to prevent thousands of patients from undergoing treatments that may prove ineffective against their specific cancer types.

Developed collaboratively by researchers at London’s Institute of Cancer Research and Dublin’s RCSI University of Medicine and Health Sciences, this method is designed with the intent to refine cancer treatment protocols significantly. In the UK, approximately 10,000 new cases of advanced bowel cancer are diagnosed each year, with an alarming increase in cases among younger adults. Bowel cancer currently holds the position of the second deadliest cancer, trailing only lung cancer. While early detection can yield survival rates close to 98%, the prognosis for advanced cases drops drastically, with five-year survival rates plummeting to around 10%.

The study focused on 117 European patients suffering from bowel cancer, all of whom had undergone treatments with chemotherapy alongside the drug bevacizumab, recently approved by the NHS in December. Bevacizumab is designed to slow cancer progression by cutting off the necessary proteins required for tumor growth. However, it is effective only for a minority of patients and can lead to serious side effects, including blood clots and gastrointestinal complications.

To enhance treatment efficacy, researchers utilized PhenMap, an advanced AI application that amalgamates the concepts of “phenotype” (the observable characteristics of an organism) and “mapping.” This tool enabled researchers to weave together complex genetic data regarding the tumors, facilitating the identification of how different patients responded to the treatment.

Through the use of PhenMap, researchers successfully identified patterns in patients’ reactions to bevacizumab and pinpointed a subgroup sharing the same genetic mutation, all of whom were at a significantly elevated risk of adverse reactions to the drug. This significant advancement has led the researchers to aspire to broaden the sample size in future studies and investigate if the insights gained can be applied to the treatment of other cancer types.

According to Anguraj Sadanandam, a professor specializing in stratification and precision medicine at the Institute of Cancer Research, the difficulty arises when bowel cancer spreads to other areas of the body, leaving patients with limited treatment options. The approval of bevacizumab on the NHS offers a positive development; however, Sadanandam notes that a majority of patients will likely not benefit from this drug, resulting in thousands potentially experiencing unwanted side effects without therapeutic gain. Until now, identifying these patients had proven challenging.

Sadanandam emphasizes that their innovative research employs sophisticated AI tools to aggregate extensive datasets, which allows for the detection of patterns that might elude human analysis. This technique helps uncover vital information concealed within patients’ tumors. “Our findings indicate that we can identify those patients who are least likely to benefit from treatment with bevacizumab,” he elaborated.

While he expresses optimism about the findings, Sadanandam stresses the necessity of validating this tool through testing with a larger cohort. He envisions that in the future, this strategy will culminate in the development of a testing protocol that clinicians can utilize, thereby enabling personalized treatment plans that optimize the likelihood of successful outcomes against various cancer types.